These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31003914)

  • 1. Epitope mapping of antibodies induced with a conserved rhinovirus protein generating protective anti-rhinovirus immunity.
    Sam Narean J; Glanville N; Nunn CM; Niespodziana K; Valenta R; Johnston SL; McLean GR
    Vaccine; 2019 May; 37(21):2805-2813. PubMed ID: 31003914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein.
    Glanville N; McLean GR; Guy B; Lecouturier V; Berry C; Girerd Y; Gregoire C; Walton RP; Pearson RM; Kebadze T; Burdin N; Bartlett NW; Almond JW; Johnston SL
    PLoS Pathog; 2013; 9(9):e1003669. PubMed ID: 24086140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Memory CD4+ T Cells Target Conserved Epitopes of Rhinovirus Capsid Proteins and Respond Rapidly to Experimental Infection in Humans.
    Muehling LM; Mai DT; Kwok WW; Heymann PW; Pomés A; Woodfolk JA
    J Immunol; 2016 Oct; 197(8):3214-3224. PubMed ID: 27591323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-reactive mouse monoclonal antibody against rhinovirus mediates phagocytosis in vitro.
    Behzadi MA; Choi A; Duehr J; Feyznezhad R; Upadhyay C; Schotsaert M; Palese P; Nachbagauer R
    Sci Rep; 2020 Jun; 10(1):9750. PubMed ID: 32546721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1.
    McLean GR; Walton RP; Shetty S; Peel TJ; Paktiawal N; Kebadze T; Gogsadze L; Niespodziana K; Valenta R; Bartlett NW; Johnston SL
    Antiviral Res; 2012 Sep; 95(3):193-201. PubMed ID: 22742898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhinovirus-induced VP1-specific Antibodies are Group-specific and Associated With Severity of Respiratory Symptoms.
    Niespodziana K; Cabauatan CR; Jackson DJ; Gallerano D; Trujillo-Torralbo B; Del Rosario A; Mallia P; Valenta R; Johnston SL
    EBioMedicine; 2015 Jan; 2(1):64-70. PubMed ID: 26137535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of human rhinovirus immunogenic epitopes for rational vaccine design.
    Stepanova E; Isakova-Sivak I; Rudenko L
    Expert Rev Vaccines; 2019 Sep; 18(9):877-880. PubMed ID: 31416365
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunodominant T-Cell Epitopes in the VP1 Capsid Protein of Rhinovirus Species A and C.
    Gaido CM; Stone S; Chopra A; Thomas WR; Le Souëf PN; Hales BJ
    J Virol; 2016 Dec; 90(23):10459-10471. PubMed ID: 27630239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization.
    Katpally U; Fu TM; Freed DC; Casimiro DR; Smith TJ
    J Virol; 2009 Jul; 83(14):7040-8. PubMed ID: 19403680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Epitopes on Rhinovirus 89 Capsid Proteins Capable of Inducing Neutralizing Antibodies.
    Niespodziana K; Cabauatan CR; Pazderova P; Vacal PC; Wortmann J; Keller W; Errhalt P; Valenta R
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections.
    Niespodziana K; Napora K; Cabauatan C; Focke-Tejkl M; Keller W; Niederberger V; Tsolia M; Christodoulou I; Papadopoulos NG; Valenta R
    FASEB J; 2012 Mar; 26(3):1001-8. PubMed ID: 22121050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myristoylated rhinovirus VP4 protein activates TLR2-dependent proinflammatory gene expression.
    Bentley JK; Han M; Jaipalli S; Hinde JL; Lei J; Ishikawa T; Goldsmith AM; Rajput C; Hershenson MB
    Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L57-L70. PubMed ID: 30908938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
    Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
    Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Conserved and Promiscuous Human Rhinovirus CD4 T Cell Epitopes.
    Gomez-Perosanz M; Fiyouzi T; Fernandez-Arquero M; Sidney J; Sette A; Reinherz EL; Lafuente EM; Reche PA
    Cells; 2021 Sep; 10(9):. PubMed ID: 34571943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations at the conserved N-Terminal of the human Rhinovirus capsid gene VP4, and their impact on the immune response.
    Naeem A; Alkadi HS; Manzoor MU; Yousaf I; Awadalla M; Alturaiki W; AlYami AS; Zafar A; Alosaimi B
    J Immunoassay Immunochem; 2024 May; 45(3):271-291. PubMed ID: 38551181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The conserved N-terminus of human rhinovirus capsid protein VP4 contains membrane pore-forming activity and is a target for neutralizing antibodies.
    Panjwani A; Asfor AS; Tuthill TJ
    J Gen Virol; 2016 Dec; 97(12):3238-3242. PubMed ID: 27902347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in developing a cross-serotype rhinovirus vaccine.
    Glanville N; Johnston SL
    Curr Opin Virol; 2015 Apr; 11():83-8. PubMed ID: 25829255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling of the human rhinovirus C capsid suggests a novel topography with insights on receptor preference and immunogenicity.
    Basta HA; Sgro JY; Palmenberg AC
    Virology; 2014 Jan; 448():176-84. PubMed ID: 24314648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
    Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J
    Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A neutralizing epitope on human rhinovirus type 2 includes amino acid residues between 153 and 164 of virus capsid protein VP2.
    Skern T; Neubauer C; Frasel L; Gründler P; Sommergruber W; Zorn M; Kuechler E; Blaas D
    J Gen Virol; 1987 Feb; 68 ( Pt 2)():315-23. PubMed ID: 2434607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.